Alentis Therapeutics has received US Food and Drug Administration (FDA) clearance for its investigational new drug (IND) application for ALE.C04 to treat Claudin-1 positive (CLDN1+) tumours.
ALE.C04 is an investigational antibody designed to target exposed CLDN1 in cancer cells.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This approval has been granted for ALE.C04 both as a monotherapy and in combination with pembrolizumab in a first-in-human clinical study in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
The planned Phase I/II clinical trial in HNSCC will begin in the second half of 2023.
Alentis chief medical officer Dr Luigi Manenti stated: “With ALE.C04, we aim to treat solid tumours in a unique way. By targeting exposed CLDN1 on cancer cells, our antibody remodels the extracellular matrix favouring T and NK-cell [natural killer cells] trafficking, which in turn directly kills CLDN1+ tumour cells and breaks the checkpoint inhibitor resistance in immune-excluded tumours.
“The high unmet medical need, strong scientific rationale and our compelling preclinical and translational data make HNSCC an ideal first indication for ALE.C04 as a monotherapy and in combination with anti-PD-1 [a protein found on T cells] treatment.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataClaudin will help treat cancer in two ways: by remodelling the extracellular matrix to enhance NK and T-cell trafficking, and by direct tumour cell killing via the effector function.
Alentis CEO Dr Roberto Iacone stated: “The IND clearance for ALE.C04 is an important step for Alentis as it marks our entry into the oncology space.
“The planned Phase 1/2 study will tell us a lot about the anti-tumour efficacy of our antibody to treat CLDN1+ tumours.”
